Cisbio Bioassays

Jan 16, 2023

Major Players Agilent Technologies, Inc., LifeSign LLC, QIAGEN, F. Hoffmann-La Roche Ltd, Enzo Biochem Inc., Merck KGaA, Cisbio Bioassays, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc, Johnson & Johnson Services, Inc, Thermo Fisher Scientific, Inc, Siemens Healthcare Private Limited, Abbott, General Electric among others Segmentation Analysis Safety biomarkers are expected to be the fastest-growing segment in 2022. The type segment includes efficacy biomarkers, safety biomarkers and others. The safety biomarkers segment is expected to witness the highest growth rate during the forecast period. A higher awareness of routine health checks, a lower attrition rate for drugs, and an increase in the number of people with cancer, cardiovascular disease, and kidney disease led to a large market share for safety biomarkers in the global biomarkers market. Cancer is expected to be the fastest-growing segment in 2022. The disease segment includes cardiovascular disorders, cancer, immunological disorders, neurological disorders and others. The cancer segment is expected to witness the highest growth rate during the forecast period. One of the world's most widely studied disorders is cancer. Throughout history, research has shown that biomarkers can be a turning point in cancer management for early detection and management. In the future, the popularity of cancer biomarkers is expected to be further boosted by a strong pipeline of products from major manufacturers related to cancer biomarkers. Diagnostics is expected to be the fastest-growing segment in 2022. The application segment includes food supplements, weight gain, vitamin deficiency, immunity strength and others. The diagnostics segment is expected to witness the highest growth rate during the forecast period. It is anticipated that the diagnostics segment will expand as chronic diseases become more prevalent, market-active enterprises develop, clinical trial candidates, increase and targeted treatment and diagnosis demand increases. Regional Analysis            The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the biomarkers market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. In the United States, six out of ten adults suffer from chronic diseases, and four out of ten have two or more chronic conditions, according to the National Center for Chronic Disease Prevention and Health Promotion's article "Chronic Diseases in America", updated in January 2021. It is anticipated that the market for biomarkers will grow significantly in the near future as they play a crucial role in the early diagnosis and treatment of chronic diseases. Further, the regional government is also focusing on identifying biomarkers for rare neurodegenerative diseases, which will create new opportunities for market growth. Country Analysis Germany Germany's biomarkers market size was valued at USD 5.14 billion in 2022 and is expected to reach USD 14.25 billion by 2030, at a CAGR of 13.6% from 2023 to 2030. Universities are increasingly collaborating with biomarker solution providers, and prominent research institutes and market players operate in the country. The market is expected to grow rapidly as biomarker testing becomes more available in the country, improving healthcare services and boosting the market in the process. China China’s biomarkers market size was valued at USD 5.35 billion in 2022 and is expected to reach USD 15.15 billion by 2030, at a CAGR of 13.9% from 2023 to 2030. Cancer and cardiovascular disease are becoming more common, resulting in increased demand for disease diagnosis using biomarker tests. Furthermore, the Ministry of Health predicts that 203 million citizens of China will be suffering from cardiovascular disease by 2029, which will boost the demand for biomarkers. India India's biomarkers market size was valued at USD 4.12 billion in 2022 and is expected to reach USD 11.5 billion by 2030, at a CAGR of 13.7% from 2023 to 2030. Cancer and cardiovascular diseases are expected to increase the demand for biomarkers in the near future due to their increasing incidence in the country. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the increasing due of the rising cases of cancer and cardiovascular diseases, propelling the growth of the market across the countries. Buy Now Full Report @  https://greyviews.com/checkout/304/single_user_license Contact Us